HomeAI · summaries
Storia in 17 fonti
GSK to acquire Nuvalent and its two cancer drugs under FDA review for $10.6B
GSK to acquire Nuvalent for $10.6B, gaining two lung cancer drugs — zidesamtinib and neladalkib — both under FDA review in 2026.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
cnbc.com
GSK in talks to acquire Nuvalent for more than $9 billion in biggest deal in over a decade: FT
The deal comes at a time of biotech dealmaking frenzy, driven by looming patent cliffs, newly buoyant public markets and drugmakers' race to bolster pipelines.
- ·
lecho.be
GSK en pourparlers pour racheter Nuvalent pour plus de 9 milliards de dollars
GSK serait en discussions avancées pour racheter la biotech Nuvalent pour 9 à 10 milliards de dollars, selon le Financial Times. L’opération, qui pourrait être conclue dès cette…
